Spinoffs

All Spinoffs

Accurine

AccUrine is a platform company, established by Yael Schneidman & Shani Shenhar Tsarfaty,  spacialised in Rapid At-Home and Point-of-Care Diagnostic Solutions via Urine. Dr. Yishai Levin from G-INCPM is the researcher from the Weizmann Institute.

Read more

Spinoffs

All Spinoffs

Promise Bio

Utilizing a cloud-based AI platform that performs unbiased, broad-range epiproteomic analyses on standard mass-spectrometry data

Read more

Spinoffs

All Spinoffs

Pheno.AI

Our mission is to improve human health by collecting, organizing and making accessible the world's largest collection of deep-phenotype multi-omics datasets, and by enabling others to do the same

Read more

Spinoffs

All Spinoffs

NextGrass

NextGrass is developing a unique grass strain that decreases water requirements by up to 90%, drastically reduced maintenance costs, and transforms lawns into a carbon positive contributor

Read more

Spinoffs

All Spinoffs

Modulight Biotherapeutics

At Modulight Biotherapeutics we are pioneering a new era of medicine for people living with neurological disorders - one that is fast-acting, precise, and designed to provide real relief without side effects.  Our mission is to help patients regain function and comfort in moments that matter most

Read more

Spinoffs

All Spinoffs

SLAM BioTherapeutics

Slam Bio is a biotech company developing a platform of very promising first-in-class human antibody-drug conjugates (ADCs) and bispecific monoclonal antibodies targeting the most challenging blood cancer (MDS, AML, CTCL and FL).

Read more

Spinoffs

All Spinoffs

Baccine

Baccine is developing a first-of-its-kind genetically engineered bacterial platform that will unleash anti-tumor immunity thereby giving new hope for cancer patients

Read more

Spinoffs

All Spinoffs

Gnomica Biotherapy

Gnomica is developing small-molecule drug inhibitors targeting bacterial pathways to treat cancer.

Read more

Actithera Secures Exclusive Rights to Innovative Covalent Chemistry Technologies from Weizmann Institute for Targeted Radiopharmaceutical Applications

14 October, 2025

Exclusive license via Yeda to two Weizmann Institute patent families from Prof. Nir London's lab, a leader in covalent drug design

Site-specific, durable and traceless protein radiolabeling approaches intended to enhance tumor selectivity and retention in radiopharmaceuticals

Integration into Actithera's platform to support design of next-generation radioligand therapies across oncology indications

Read more

CLISEQ, 10X Genomics and Weizmann Institute to Investigate Single Cell Applications in Hematology Clinical Diagnostics

09 September, 2025

Introducing CLISEQ – a new spinoff from Yeda / Weizmann Institute of Science, with the bold vision of transforming hematology diagnostics.
Instead of relying on invasive bone marrow aspiration, CLISEQ is pioneering single-cell analysis from peripheral blood, aiming to improve outcomes for patients with hematologic disorders and unlock the next generation of blood profiling for diagnostics and monitoring.

Read more

Pages

Subscribe to YEDA Technology Transfer RSS